Trial Information

Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.

This is a prospective multicenter study to investigate the predictive value of molecular
markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the
previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the
expression in curettage material in relation to lymph node metastasis and prognosis among
endometrial carcinoma patients. We also want to investigate the distribution of genetic
alterations in fresh frozen tumor tissue in order to design prospective randomized treatment
trials of metastatic endometrial cancer based on molecular profile. There will be a special
emphasis on disturbances in the pathways influenced by new targeted therapy, such as
inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor
pathways.